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ABSTRACT
The objectives of the study were to determine the contribution, in
mice, of members of the flavin-containing monooxygenase (FMO)
family to the production of trimethylamine (TMA) N-oxide (TMAO),
a potential proatherogenic molecule, and whether under normal
dietary conditions differences in TMAO production were associated
with changes in plasmacholesterol concentration orwith an index of
atherosclerosis (Als). Concentrations of urinary TMA and TMAO and
plasma cholesterol were measured in 10-week-old male and female
C57BL/6J and CD-1 mice and in mouse lines deficient in various
Fmo genes (Fmo12/2, 22/2, 42/2, and Fmo52/2). In femalemicemost
TMA N-oxygenation was catalyzed by FMO3, but in both genders
11%–12% of TMA was converted to TMAO by FMO1. Gender-, Fmo
genotype-, and strain-related differences in TMAO production were
accompanied by opposite effects on plasma cholesterol concentra-
tion. Plasma cholesterol was negatively, but weakly, correlated with
TMAO production and urinary TMAO concentration. Fmo genotype
had no effect on Als. There was no correlation between Als and
either TMAO production or urinary TMAO concentration. Our results
indicate that under normal dietary conditions TMAO does not
increase plasma cholesterol or act as a proatherogenic molecule.
Introduction
A correlation between plasma trimethylamine (TMA) N-oxide
(TMAO) concentrations and atherosclerotic plaque size has been
reported in atherosclerosis-prone mice fed on diets supplemented with
dietary precursors of TMA (Wang et al., 2011; Koeth et al., 2013).
TMAO production is the result of a two-step process, requiring interplay
between commensal gut bacteria and the host (Fennema et al., 2016).
This process involves the liberation of TMA from dietary precursors,
such as choline, carnitine, and TMAO itself (Mitchell et al., 2002;
Fennema et al., 2016), and the subsequent host-dependent hepatic
N-oxygenation of TMA to TMAO (Ayesh et al., 1993). In humans, this
oxygenation reaction is catalyzed by flavin-containing monooxygenase
(FMO) 3 (Dolphin et al., 1997; Lang et al., 1998). Healthy individuals
excrete in their urine ;95% of total TMA (TMA + TMAO) as TMAO
and ;5% as TMA (Al-Waiz et al., 1987b). Individuals homozygous or
compound heterozygous for mutations that severely affect FMO3
activity have impaired N-oxygenation of TMA and suffer from the
inherited metabolic disorder primary trimethylaminuria (Dolphin et al.,
1997; Phillips and Shephard, 2015; Shephard et al., 2015).
There are five functional FMOs in humans: FMO1, 2, 3, 4, and
5 (Phillips et al., 1995; Hernandez et al., 2004). Of these, FMO2 is not
expressed in themajority of humans (Dolphin et al., 1998; Veeramah et al.,
2008). FMO4 is expressed in very low amounts and little is known about
the role of this FMO (Dolphin et al., 1996; Zhang and Cashman, 2006). In
human liver, at the time of birth there is a switch in the FMO genes
expressed:FMO3 is switched on andFMO1 is switched off (Dolphin et al.,
1996; Koukouritaki et al., 2002). The FMO1 gene continues to be
expressed in humans in the kidney (Dolphin et al., 1996) through the use of
an alternative promoter (Shephard et al., 2007). Therefore, after birth,
humans primarily express two FMO genes in their liver,FMO3 andFMO5
(Dolphin et al., 1996; Overby et al., 1997; Koukouritaki et al., 2002; Zhang
and Cashman, 2006). However, all other mammals studied continue to
express FMO1 in adult liver (Phillips et al., 2007).
In mice, there is an age-related gender difference in the expression of
Fmo genes in the liver: male mice, post 5–6 weeks of age, switch off the
expression of Fmo3, and thus represent natural liver-specific knockouts
for FMO3 (Falls et al., 1995; Janmohamed et al., 2004). Adult malemice
consequently express two Fmo genes, Fmo1 and Fmo5, in liver. In
contrast, adult female mice, in addition to expressing Fmo1 and Fmo5,
continue to express Fmo3 in liver. The gender-related differences in
Fmo gene expression in mice are due to the influence of sex steroids
(Falls et al., 1997).
Reports associating TMAO with atherosclerosis and increased risk of
cardiovascular disease (Wang et al., 2011; Koeth et al., 2013) are largely
based on studies involving concentrations of precursors of TMA or of
TMAO itself far in excess of those found under normal dietary
conditions and it is not clear whether atherosclerosis risk factors are
influenced by physiologically relevant concentrations of TMAO.
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Here, we report the use of male and female mice of two different
strains and knockout mouse lines deficient in various FMOs (Fmo12/2,
22/2, 42/2, and Fmo52/2) to determine the contribution of particular
FMOs to the production of TMAO in vivo and to investigate whether,
under normal dietary conditions, differences in TMAO production are
associated with changes in plasma cholesterol concentration or with an
index of atherosclerosis (Als). We found that in females conversion of
TMA to TMAO is catalyzed mainly by FMO3, an enzyme that is absent
from the liver of adult males (Falls et al., 1995; Janmohamed et al.,
2004), but in both genders FMO1 contributes to TMAO production.
Differences in TMAO production were accompanied by opposite effects
on plasma cholesterol concentration and were not correlated with Als.
Our results indicate that at physiologically relevant concentrations
TMAO does not act as a proatherogenic molecule in mice.
Materials and Methods
Animal Maintenance. C57BL/6J wild-type (WT) mice and two knockout
mouse lines (Fmo12/2, 22/2, 42/2, and Fmo52/2, each of which was back-
crossed for eight generations on the C57BL/6J background) were bred at
University College London. Generation of the knockout mouse lines has been
described previously (Hernandez et al., 2009; Gonzalez Malagon et al., 2015).
CD-1mice were purchased from Charles River (Margate, Kent, United Kingdom)
and allowed to acclimatize for 14 days before sample collection. All mice were
housed in the same room and given free access to water and fed ad libitum with a
standard chow diet (2018 Teklad Global 18% Protein Rodent Diet, Harlan
Laboratories, Inc., Madison, WI), which contained a choline content of 1.2 g/kg.
Blood and urine were collected from 10-week-old male and female mice between
10:00 AM and 12:00 PM. Animal procedures were carried out in accordance with
the U.K. Animal Scientific Procedures Act (https://www.gov.uk/government/
publications/consolidated-version-of-aspa-1986) and with local ethics committee
approval (Animal Welfare and Ethical Review Body) (http://www.ucl.ac.uk/
research/integrity/animal-research-accordion/awerb-responsibilities) and appro-
priate Home Office licenses.
Urine Analyses. Concentrations of TMA, TMAO, and creatinine in urine
samples were determined by capillary liquid chromatography electrospray
ionization mass spectrometry as described previously (Veeravalli et al., 2017).
Production of TMAO was assessed by determining the percentage of total TMA
excreted as TMAO, using the following formula: [TMAO/(TMA + TMAO)] 
100 (Al-Waiz et al., 1989). To control for differences in urine concentration,
urinary TMAO and TMA concentrations were expressed relative to urinary
creatinine concentration.
Plasma Metabolites. Blood samples were collected and plasma isolated as
described previously (Hough et al., 2002). Concentrations of total cholesterol and
high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol
were determined via an autoanalyzer at the Medical Research Council Mamma-
lian Genomics Unit (Harwell, Oxfordshire, United Kingdom) as described
previously (Hough et al., 2002). Als was calculated as (total plasma cholesterol2
HDL cholesterol)/HDL cholesterol (Gao et al., 2014).
Quantitative Real-Time Polymerase Chain Reaction. RNA was isolated
from liver and individual mRNAs were quantified by quantitative real-time
polymerase chain reaction, according to the DDCTmethod (Liu and Saint, 2002),
as described previously (Veeravalli et al., 2014). Primers for SREBP-2,
3-hydroxy-3-methylglutaryl-CoA reductase, CYP7A1, CYP27A1, SR-B1,
ABCG5, ABCG8, and ABCB11 were as described previously (Gonzalez
Malagon et al., 2015). Additional forward and reverse primer sequences for
3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and squalene synthase
were the following: HMGCS1 forward 59GTGGCACCGGATGTCTTTG39 and
HMGCS1 reverse 59ACTCTGACCAGATACCACGTT39, respectively; and
squalene synthase forward 59ATGGAGTTCGTCAAGTGTCTAGG39 and squa-
lene synthase reverse 59CGTGCCGTATGTCCCCATC39, respectively. The use
of a geNormTM kit and geNorm software (Primer Design Ltd., Southampton,
Hampshire, United Kingdom), as described previously, identified glyceraldehyde-
3-phosphate dehydrogenase as the most suitable housekeeping gene for liver
(Veeravalli et al., 2014).
Statistical Analyses. Values are given as mean 6 S.E.M. Statistical
significance was determined using an unpaired two-tailed student’s t test.
Statistical significance is represented as *P , 0.05; **P , 0.01; ***P , 0.001.
Correlations were assessed using Pearson’s r.
Results
Mouse Gender, Fmo Genotype, and TMAO Production. Urine
frommale and female C57BL/6JWTmice and twoFmo-knockout lines,
Fmo12/2, 22/2, 42/2, and Fmo52/2, was analyzed for TMAO and
TMA content. The FMO isoforms expressed in the livers of these
animals at 10 weeks of age are given in Table 1. Irrespective of Fmo
genotype, the percentage of total TMA (TMA + TMAO) excreted as
TMAO was far less in male than in female mice (Fig. 1, A and B).
In both male and female Fmo12/2, 22/2, and 42/2 mice the
proportion of total TMA excreted as TMAO was less than in gender-
matched C57BL/6J WT mice (Fig. 1, A and B). In males the proportion
of total TMA excreted as TMAO by Fmo12/2, 22/2, and 42/2 mice
(8.4% 6 1.6%) was 56% less than by WT mice (19.5% 6 2.6%),
whereas in females TMAO excretion by Fmo12/2, 22/2, and 42/2mice
(70.7%6 0.1%) was 14% less than byWTmice (83.2%6 1.3%). There
was no increase in expression of the Fmo3 gene in the liver of Fmo12/2,
22/2, and 42/2 mice, in response to deletion of Fmo genes (Hernandez
et al., 2009). The results, therefore, indicate that in mice FMO 1, 2, or
4 contributes to theN-oxygenation of TMA. It is most likely to be FMO1
because this enzyme is expressed in adult mouse liver, the site of TMA
N-oxygenation, whereas FMOs 2 and 4 are not expressed in this tissue
(Janmohamed et al., 2004). Thus, in bothmale and femalemice, 11%–12%
of TMA is converted to TMAO by FMO1. In Fmo52/2 mice the
proportion of total TMA excreted as TMAO was the same as that in WT
mice, in both males and females, indicating that FMO5 plays no role in the
conversion of TMA to TMAO in vivo.
Mouse Gender, Fmo Genotype, and Plasma Cholesterol
Concentration. Increased concentration of TMAO has been linked to
the formation of proatherogenic plaques (Wang et al., 2011), of which
cholesterol is an important component. The gender- and Fmo genotype–
related differences in TMAO production (Fig. 1) led us to investigate the
effect of gender and Fmo genotype on plasma cholesterol concentra-
tions. Plasma concentrations of total, HDL, and LDL cholesterol were
determined in male and female C57BL/6J WT, Fmo12/2, 22/2, 42/2,
and Fmo52/2 mice (Table 2). In WT mice and in both knockout mouse
lines females had significantly lower plasma concentrations of total and
HDL cholesterol than did their male counterparts, but the plasma
concentration of LDL cholesterol was similar in male and female mice.
Therefore, the greater production of TMAO in female mice was
accompanied by significantly lower plasma concentrations of total and
HDL cholesterol.
Both male and female Fmo12/2, 22/2, and 42/2 mice had higher
plasma concentrations of total and HDL cholesterol than did their WT
counterparts, and in females the plasma concentration of LDL cholesterol
was also higher than in WT mice (Table 2). Based on the tissue-specific
expression patterns of FMOs in mice (Janmohamed et al., 2004), the
higher plasma cholesterol concentration observed in Fmo12/2, 22/2, and
42/2 mice is likely to be due to disruption of the Fmo1 gene, which is
expressed in liver, and not to disruption ofFmo2 andFmo4, which are not
TABLE 1
FMO isoforms expressed in the livers of 10-week-old WT and Fmo-knockout
mouse lines
Mouse Line Male Female
C57BL/6J WT FMO1, FMO5 FMO1, FMO3, FMO5
Fmo12/2, 22/2, 42/2 FMO5 FMO3, FMO5
Fmo52/2 FMO1 FMO1, FMO3
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expressed in liver. Consequently, our results indicate that in mice FMO1
plays a role in the regulation of plasma cholesterol concentration.
Comparison of Fmo52/2 and WT mice revealed that plasma concentra-
tions of total and HDL cholesterol were similar in females and lower in
males (Table 2), indicating that in males there is a role for FMO5 in
promoting plasma cholesterol concentration.
Mouse Gender, Fmo Genotype, and Atherosclerosis Index. We
next investigated the effect of Fmo genotype on Als. There was no
significant difference in Als between C57BL/6J WT mice and either of
the two knockout lines, in either male or female animals (Fig. 2).
Similarly, there was no difference in Als between males and females of
either WT or Fmo52/2mice, despite production of TMAO being 4-fold
greater in females (Fig. 1). However, in Fmo12/2, 22/2, and 42/2mice,
Als was ;26% lower in males than in females (Fig. 2).
Mouse Strain, TMAO, Plasma Cholesterol, and Als. We also
investigated the relationship between TMAO production, plasma total
cholesterol, and Als in another mouse strain, CD-1. In males, the urinary
concentration of TMAO (mM/mM creatinine) was 0.18 6 0.02 (n = 5)
for CD-1 mice and 0.70 6 0.03 (n = 4) for C57BL/6J WT mice. For
females the values were 0.66 6 0.06 (CD-1, n = 6) and 2.73 6 0.20
(C57BL/6J WT, n = 4). Therefore, for both genders the urinary
concentration of TMAO of CD-1 mice was ;75% less than that of
C57BL/6J WT mice (P , 0.0001), and as was the case for C57BL/6J
WT mice it was higher in female than in male animals (P , 0.0001).
The plasma concentration of total cholesterol of CD-1 mice was
significantly higher than that of C57BL/6J WT mice in both genders
(Table 2). Inmales,Alswas significantly higher inCD-1 (0.6860.08, n=5)
than in C57BL/6JWT (0.386 0.02, n = 4) (P, 0.05), but not in females
(CD-1: 0.51 6 0.04, n = 6; C57BL/6J WT: 0.44 6 0.02, n = 4).
Therefore, although CD-1 mice had substantially lower urinary
concentrations of TMAO than did C57BL/6J mice, they had higher
plasma concentrations of total cholesterol, in both genders, and in males
they had had higher Als.
Correlations of TMAO with Plasma Cholesterol or Als. Our
results indicate an inverse relationship between TMAO production and
the plasma concentration of total cholesterol. Therefore, we investigated
whether there was a correlation between total plasma cholesterol
concentration and either TMAO production, which is measured by the
percentage of total TMA excreted as TMAO, or the urinary concentra-
tion of TMAO. Analysis of male and female C57BL/6J WT, CD-1 WT,
Fmo12/2, 22/2, 42/2, andFmo52/2mice (a total of 34 animals) showed
a weak negative correlation between plasma total cholesterol concen-
tration and both TMAO production and urinary TMAO concentration
(Supplemental Fig. 1, A and B; Table 3). There was no correlation
between Als and either TMAO production or urinary TMAO concen-
tration (Supplemental Fig. 1, C and D; Table 3).
Quantification of mRNAs Encoding Proteins Involved in
Cholesterol Synthesis, Uptake, Transport, or Disposition.
Fmo12/2, 22/2, and 42/2 mice, both male and female, had higher
plasma concentrations of total and HDL cholesterol compared with their
WT and Fmo52/2 counterparts (Table 2). To attempt to identify a
potential basis for the elevated plasma concentrations of cholesterol and
HDL cholesterol in Fmo12/2, 22/2, and 42/2 mice, mRNAs encoding
proteins involved in cholesterol biosynthesis, cholesterol uptake and
transport, and bile acid synthesis and secretion were quantified by
quantitative real-time polymerase chain reaction in livers of male
Fmo12/2, 22/2, 42/2, and C57BL/6J WT mice (Table 4).
The mRNA for SREBP-2, a transcription factor that upregulates
expression of genes involved in cholesterol synthesis, was more
abundant in Fmo12/2, 22/2, and 42/2 than in C57BL/6J WT animals
(Table 4). Although relatively small, the increased abundance of the
mRNA for this transcription factor may contribute to the elevated plasma
cholesterol observed in Fmo12/2, 22/2, and 42/2 mice. However, the
abundance of mRNAs encoding proteins involved in cholesterol
biosynthesis was not increased (Table 4).
SR-B1 mRNA was more abundant in the Fmo12/2, 22/2, and 42/2
mice (Table 4). Because of the role of SR-B1 in promoting cholesterol
uptake (Varban et al., 1998; Ji et al., 1999) the increase in the abundance
of its mRNA may be an attempt to reduce the elevated concentration of
plasma HDL cholesterol in Fmo12/2, 22/2, and 42/2mice. The mRNA
for ABCB-11, which encodes the bile salt export pump located on
the canalicular membrane of hepatocytes, a protein that controls the
Fig. 1. Effect of Fmo genotype and gender on TMAO production. Urinary excretion
of TMAO as a percentage of total TMA (TMA + TMAO) in male (A) and female
(B) mice. n = 3–5. *P , 0.05; ***P , 0.001.
TABLE 2
Effect of Fmo genotype and gender on plasma concentrations of total, HDL, and LDL cholesterol
The P values are for comparisons of the values for each mouse line or strain vs. those for C57BL/6J WT mice of the same gender: n =





C57BL/6J WT Male 2.88 6 0.09 2.09 6 0.07 0.54 6 0.02
C57BL/6J WT Female 2.41 6 0.13 1.67 6 0.08 0.48 6 0.03
Fmo12/2, 22/2, 42/2 Male 4.03 6 0.12*** 3.05 6 0.09*** 0.61 6 0.03
Fmo12/2, 22/2, 42/2 Female 3.41 6 0.13** 2.39 6 0.11** 0.69 6 0.01**
Fmo52/2 Male 2.63 6 0.05* 1.88 6 0.03* 0.52 6 0.01
Fmo52/2 Female 2.21 6 0.11 1.53 6 0.08 0.48 6 0.03
CD-1 Male 3.76 6 0.26* 2.28 6 0.21 0.66 6 0.05
CD-1 Female 3.21 6 0.17* 2.14 6 0.15* 0.67 6 0.05*
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rate-limiting step in hepatic bile secretion (Henkel et al., 2013), was
more abundant in the Fmo12/2, 22/2, and 42/2 mice (Table 4). The
increase in ABCB-11 mRNA may be in response to increased SR-B1-
mediated cholesterol uptake and suggests that bile flow from the liver to
the intestine may be greater in Fmo12/2, 22/2, and 42/2 mice than in
WT mice. However, there was no difference between Fmo12/2, 22/2,
42/2, and WT mice in the abundance of mRNAs encoding either
CYP7A1 or CYP27A1 (Table 4), two enzymes important in bile acid
synthesis (Norlin and Wikvall, 2007).
Discussion
Our results show that female mice produced far more TMAO than did
male animals. This marked gender difference is consistent with previous
findings (Li et al., 2013) and can be explained by the fact that at
5–6 weeks of age the expression of the gene encoding FMO3, the major
enzyme involved in conversion of TMA to TMAO in both human and
mouse (Dolphin et al., 1997; Lang et al., 1998; Zhang et al., 2007), is
switched off in the liver of male, but not female, mice (Falls et al., 1995;
Janmohamed et al., 2004).
In both male and female C57BL/6J WT mice FMO1, but not FMO5,
contributed to TMAO production, with 11%–12% of TMA being
converted to TMAO by the action of FMO1. Consequently, in females
the majority of TMAO was produced by hepatic FMO3, but in males,
which lack hepatic FMO3,most of themuch lower production of TMAO
was derived from the action of FMO1. Our results in vivo are consistent
with those found in vitro (Bennett et al., 2013).
Results from Fmo12/2, 22/2, and 42/2mice indicate that despite the
disruption of genes encoding FMO1, FMO2, and FMO4 and the lack of
hepatic FMO3 males still produced a small amount of TMAO. The
reason for this is unclear, but could be due to the action of FMO3
in tissues other than liver, for instance, adult males continue to
express FMO3 in Clara cells of the lung (Janmohamed et al., 2004).
Other possibilities include the action of non-FMO enzymes or the
production of TMAO from TMA by gut bacteria (reviewed by
Fennema et al., 2016).
In contrast to mice and other mammals investigated, humans do not
express FMO1 in liver after birth (Dolphin et al., 1996; Koukouritaki
et al., 2002). Thus, in adult humans FMO1 cannot contribute to hepatic
TMAO production. Although FMO1 is expressed in human kidney
(Dolphin et al., 1996) and small intestine (Yeung et al., 2000),
conversion of TMA to TMAO was not detected in microsomes isolated
from these tissues (Lang et al., 1998). Recombinant human FMO1 can
catalyze the conversion of TMA to TMAO but only at high (5 mM)
concentrations of TMA (Lang et al., 1998). In humans, the concentration
of TMA never reaches the mM range, even in individuals with severe
trimethylaminuria (Al-Waiz et al., 1987a); this is in contrast to mice,
which excrete TMA in the mM range (Li et al., 2013). Consequently,
FMO1 is unlikely to contribute to TMAO production in humans.
Gender-, Fmo genotype–, and strain-related differences in TMAO
production were in all cases accompanied by opposite effects on plasma
total cholesterol concentration. Plasma total cholesterol concentration
was negatively, but weakly, correlated with both TMAO production and
urinary TMAO concentration.
Our results indicate that both FMO1 and FMO5 are involved in the
regulation of plasma cholesterol concentration, but with opposing
effects: FMO1 acts to decrease plasma cholesterol concentration in
both male and female animals, whereas FMO5 promotes an increase in
plasma cholesterol concentration in males. The latter is consistent with
our previous finding that FMO5 promotes an age-related increase in
plasma cholesterol concentration, which by 30 weeks of age is evident in
both genders (Gonzalez Malagon et al., 2015).
Als was not influenced by Fmo genotype and, despite relatively large
gender-related differences in production of TMAO, in only one of
the three mouse lines, Fmo12/2, 22/2, and 42/2, was Als influenced
by gender, and then to a relatively small extent. There was no correla-
tion between Als and either TMAO production or urinary TMAO
concentration.
Several studies of mice have implicated TMAO as a proatherogenic
molecule. Most of these have been done on mice carrying an ApoB
transgene or on ApoE2/2 knockout animals (Wang et al., 2011; Bennett
et al., 2013; Koeth et al., 2013; Yang et al., 2014) in an attempt to
better mimic the situation in humans, a species in which plasma LDL
cholesterol constitutes a higher proportion of total cholesterol than is
found in mice. Many of these studies involved feeding the animals with
precursors of TMA or with TMAO itself in amounts far in excess of
normal dietary levels; for instance, in some cases diets were supple-
mented with concentrations of choline as high as 13 g/kg, more than
10 times that present in the standard chow diet used in our study.
In contrast, a study by Mayr et al. (2005) found no significant difference
in TMAO concentration in the aortas of 18-month-old ApoE2/2
and ApoE+/+mice, despite the former having severe aortic atheroscle-
rotic lesions. The lesion formation in ApoE2/2 mice was ascribed
not to increased TMAO but to an increase in oxidative stress (Mayr
et al., 2005).
Fig. 2. Effect of Fmo genotype, gender, and mouse strain on Als. n = 3–5. *P, 0.05.
TABLE 3
Correlation between plasma total cholesterol concentration or Als and TMAO
Each correlation analysis was performed on a total of 34 animals. Results from individual animals are shown in Supplemental Fig. 1.
Correlation r R2 P value
Plasma total cholesterol vs. [TMAO/(TMA + TMAO)]  100 20.357 0.127 0.038
Plasma total cholesterol vs. TMAO/creatinine 20.464 0.215 0.006
Als vs. [TMAO/(TMA + TMAO)]  100 0.136 0.019 0.442
Als vs. TMAO/creatinine 20.151 0.023 0.395
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A role for TMAO in predisposition to cardiovascular disease is
counterintuitive given that the richest dietary source of TMAO is marine
fish, the consumption of which has been shown to exert beneficial effects
on the circulatory system (Zhang et al., 1999; Takata et al., 2013).
Consistent with this, a study of C57BL/6J WT mice found that the
increase in Als associated with a high-fat diet was prevented by dietary
supplementation with TMAO, suggesting a protective effect of TMAO
with regard to atherosclerosis (Gao et al., 2014).
In our study we used C57BL/6J and CD-1 mice and two Fmo gene
knockout mouse lines (Fmo12/2, 22/2, 42/2, and Fmo52/2) generated
on a C57BL/6J background to investigate, under normal dietary
conditions, the effect of mouse gender, mouse strain, and Fmo genotype
on TMAO production, plasma cholesterol concentration, and Als. We
elected not to complicate the experimental design or data interpretation
by the use of an additional genotype change, such as the disruption of
ApoE or the presence of an ApoB transgene, or by supplementation of
diet with TMA precursors. Our results indicate an inverse relationship
between TMAO production and the plasma concentration of total
cholesterol, and that neither plasma cholesterol concentration nor Als is
positively correlated with either TMAO production or urinary TMAO
concentration. Indeed, there is a negative, albeit it weak, correlation
between plasma cholesterol concentration and both TMAO production
and urinary TMAO concentration. Our results, therefore, indicate that
under normal dietary conditions TMAO does not act as a proatherogenic
molecule.
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